Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson cOVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2024
198
Period ended Dec 29, 2024
Change on a year earlier
-82.3%
1,117 in FY2023
History
6 years
Since FY2019
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 29, 2024 | 198 | -82.3% | Form 10-K (filed 2025-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 1,117 | -45.8% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Jan 1, 2023 | 2,059 | +17.6% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 1,751 | – | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 0 | – | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 0 | – | Form 10-K (filed 2022-02-17) ↗ |
Breakdown
What makes up covid-19 vaccine (ad26.cov2.s) [reported through fy2024q4] — international sales ($m)
Cite this data
StockData. (2026). Johnson & Johnson COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M) ($M), annual FY2019–FY2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_covid19_intl
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.